Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Heal Clinics is a health and wellness service provider offerring the HEALcare keto...
Heal Clinics is a health and wellness service p...
Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...
Founded in 1996 as a spinoff from the Harvard-M...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology compan...
Axonics Modulation Technologies, Inc. (NASDAQ:A...
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Geron is a late-stage clinical biopharmaceutical company focused on the developmen...
Geron is a late-stage clinical biopharmaceutica...
We are a global frontrunner in making oral vaccines a reality. Weâve created a p...
We are a global frontrunner in making oral vacc...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
Join the National Investor Network and get the latest information with your interests in mind.